The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by ...
INCHEON, South Korea--(BUSINESS WIRE)--Celltrion, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved INFLECTRA™ (biosimilar infliximab) ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — Researchers have observed a “modest uptake” in the use of biosimilars for infliximab in the past 18 ...
-- Subsequent entry biologic (SEB) medicine provides a lower-cost, high-quality, safe and effective therapy for rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and ...
A study released today that pitted Hospira's biosimilar Inflectra against its reference drug Remicade in patients with rheumatoid arthritis is good news for Hospira ...
Melbourne, Australia, Aug 20, 2015 – Hospira today announced that Inflectra™ (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback